GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Insmed Inc (LTS:0JAV) » Definitions » Cyclically Adjusted PB Ratio

Insmed (LTS:0JAV) Cyclically Adjusted PB Ratio : 23.41 (As of Jun. 03, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Insmed Cyclically Adjusted PB Ratio?

As of today (2025-06-03), Insmed's current share price is $71.40. Insmed's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $3.05. Insmed's Cyclically Adjusted PB Ratio for today is 23.41.

The historical rank and industry rank for Insmed's Cyclically Adjusted PB Ratio or its related term are showing as below:

LTS:0JAV' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 2.56   Med: 5.9   Max: 25.4
Current: 22.75

During the past years, Insmed's highest Cyclically Adjusted PB Ratio was 25.40. The lowest was 2.56. And the median was 5.90.

LTS:0JAV's Cyclically Adjusted PB Ratio is ranked worse than
96.58% of 672 companies
in the Biotechnology industry
Industry Median: 1.475 vs LTS:0JAV: 22.75

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Insmed's adjusted book value per share data for the three months ended in Mar. 2025 was $0.545. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $3.05 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Insmed Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Insmed's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Insmed Cyclically Adjusted PB Ratio Chart

Insmed Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.56 6.36 4.98 8.77 21.54

Insmed Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.96 20.05 22.20 21.54 24.22

Competitive Comparison of Insmed's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Insmed's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Insmed's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Insmed's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Insmed's Cyclically Adjusted PB Ratio falls into.


;
;

Insmed Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Insmed's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=71.40/3.05
=23.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Insmed's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Insmed's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.545/134.9266*134.9266
=0.545

Current CPI (Mar. 2025) = 134.9266.

Insmed Quarterly Data

Book Value per Share CPI Adj_Book
201506 5.917 100.684 7.929
201509 5.485 100.392 7.372
201512 5.043 99.792 6.819
201603 4.565 100.470 6.131
201606 4.049 101.688 5.372
201609 3.520 101.861 4.663
201612 2.491 101.863 3.300
201703 1.960 102.862 2.571
201706 1.338 103.349 1.747
201709 5.502 104.136 7.129
201712 4.713 104.011 6.114
201803 5.675 105.290 7.272
201806 4.811 106.317 6.106
201809 3.780 106.507 4.789
201812 2.694 105.998 3.429
201903 1.858 107.251 2.337
201906 3.997 108.070 4.990
201909 3.404 108.329 4.240
201912 2.918 108.420 3.631
202003 2.300 108.902 2.850
202006 3.996 108.767 4.957
202009 3.507 109.815 4.309
202012 2.685 109.897 3.297
202103 1.952 111.754 2.357
202106 4.608 114.631 5.424
202109 4.265 115.734 4.972
202112 3.457 117.630 3.965
202203 1.004 121.301 1.117
202206 0.369 125.017 0.398
202209 -0.246 125.227 -0.265
202212 0.648 125.222 0.698
202303 -0.327 127.348 -0.346
202306 -1.091 128.729 -1.144
202309 -2.023 129.860 -2.102
202312 -2.243 129.419 -2.338
202403 -3.129 131.776 -3.204
202406 0.233 132.554 0.237
202409 2.703 133.029 2.742
202412 1.591 133.157 1.612
202503 0.545 134.927 0.545

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Insmed  (LTS:0JAV) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Insmed Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Insmed's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Insmed Business Description

Industry
Traded in Other Exchanges
Address
700 US Highway 202/206, Bridgewater, NJ, USA, 08807
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Insmed Headlines

No Headlines